https://www.selleckchem.com/pr....oducts/ganetespib-st
sTg levels 1 occurred in 26 (35%) of patients with nsTg 0.1-2.0 ng/ml, 11 (15%) had structural incomplete response. None of the patients with sTg levels 1 ng/ml developed structural or functional disease over the follow-up period. Suppressed thyroglobulin (nsTg 0.1 ng/ml) indicates a very low risk of recurrence that does not require stimulation. Stimulated thyroglobulin is beneficial with nsTg 0.1-2 ng/ml for re-classifying patients and estimating their risk for incomplete responses over a 7 years follow-up peri
Like
Comment
Share
